tbuckley/cabot-search huggingface dataset:
Biochemical Properties of Neoplastic Cell Mitochondria2
Authors: Michael T. White, D. V. Arya, K. K. Tewari
Journal: JNCI Journal of the National Cancer Institute (1974)

Mitochondria from monolayer cultures of Novikoff hepatomacells were studied for their biochemical and structural organization and compared with mitochondria from solid Novikoff hepatoma and normal liver. Cultured cell and tumor mitochondria were similar in both ultrastructure and biochemical properties. Both differed distinctly from liver mitochondria, in that they had drastically reduced activities of several flavoprotein enzymes associated with their outer and Inner membranes and altered morphology of their matrix as evident from electron micrographs. The alterations we observed in the Novikoff hepatoma mitochondria were not the result of varied growth conditions but were inherent in these neoplastic cells. Mitochondria from another neoplastic cell line, hamster melanoma CCL 49, grown in vitro were compared to mitochondria from cultures of a non-neoplastic cell line, hamster embryo Nil 2. Melanoma cell mitochondria showed reductions in outer and inner membrane flavoproteins similar to those observed in Novikoff hepatoma mitochondria. There were significant reductions in the activities of NADH oxidase, NADH-cytochrome c reductase, and adenylate kinase. In addition, monoamine oxidase was absent.
Carcinogenicity of Aflatoxin B1 in Rhesus Monkeys: Two Additional Cases of Primary Liver Cancer2
Authors: Richard H. Adamson, Pelayo Correa, Susan M. Sieber, K. Robert McIntire, Dan W. Dalgard
Journal: JNCI Journal of the National Cancer Institute (1976)

Three of 42 (7%) monkeys given aflatoxin B1 (AFB1) for longer than 2 years have developed primary malignant neoplasms of the liver. Liver biopsies performed at intervals during aflatoxin administration revealed that neoplasia was preceded by pathologic lesions of the liver, including toxic hepatitis, proliferation of pseudotubules, and hyperplastic nodules. Serum α-feto-protein levels, monitored in one of the monkeys by radioimmunoassay, paralleled tumor growth and recurrence of the hepatocellular carcinoma. Normal serum α-fetoprotein levels were noted for a monkey with hemangioendothelial sarcoma. Our results implicate AFB1 as a liver carcinogen in monkeys and add additional support to the hypothesis that humans exposed to this substance may be at risk of developing liver cancer.
Effect of breakthrough pain on functional status, pain interference, and disability in cancer patients: Findings from the national breakthrough pain survey.
Authors: Arvind Narayana, Nathaniel Katz, Alicia Shillington, Judith J Stephenson, Carla B Frye, Russell Portenoy
Journal: Journal of Clinical Oncology (2013)

6627 Background: Few studies have evaluated the epidemiology of breakthrough pain (BTP) in community-dwelling populations with cancer and chronic pain. The National Breakthrough Pain Survey (NBTPS) assessed the prevalence, characteristics, and impact of BTP in a large commercially-insured population and determined the BTP-associated functional impairments and disability in cancer patients with controlled, persistent pain. Methods: Administrative claims from the HealthCore Integrated Research Database were utilized to identify commercially-insured adult patients with ≥2 medical claims at an interval ≥3 months with an ICD-9-CM code indicating a chronic pain condition (cancer or noncancer) and ≥3 opioid prescription claims. Patients were called and, after consent, completed the Brief Pain Inventory (BPI), Sheehan Disability Scale (SDS), and 12-Item Short-Form Health Survey (SF-12) by interview. Data from patients with cancer and controlled, persistent pain were included in this subanalysis. Results: Of 2198 patients surveyed, 1279 had controlled, persistent pain. Of these, 145 had cancer pain, 77.2% of whom reported BTP (BTP, 112; no BTP, 33). Compared to those without BTP, cancer patients with BTP had significantly higher total BPI pain interference scores (mean±SD 34.7±14.5 vs 23.4±16.7, P=.001) and significantly greater global functional impairment on the SDS (mean±SD 16.8±8.3 vs 12.4±8.3, P=.028). There also was a non-significant finding of decreased quality of life, as assessed by SF-12 physical and mental component scale scores, among cancer patients with BTP vs no BTP (mean±SD 27.8±9.1 vs 32.2±10.1, P=.11, and 47.0±11.9 vs 49.4±11.6, P=1.0, respectively). Conclusions: In a sample of commercially-insured patients, cancer patients with controlled, persistent pain and BTP had greater pain-related functional impairments and disability than those with controlled, persistent pain and no BTP. These data suggest that BTP is clinically important among populations receiving cancer care in the community.
A Pre-Clinical Model Of Hematopoietic Stem Cell Based Immunotherapy For Cancer Utilizing The NY-ESO-1 T-Cell Receptor and sr39TK PET Reporter / Suicide Gene
Authors: Eric H. Gschweng, Melissa N. McCracken, Thinle Chodon, Richard C Koya, Michael L Kaufman, Michelle Ho, Navdeep Saini, Roger P. Hollis, Antoni Ribas, Satiro N. De Oliveira, Owen N. Witte, Donald B. Kohn
Journal: Blood (2013)
Down-regulation of the intrarenal renin-angiotensin system in the aging rat.
Authors: F F Jung, T M Kennefick, J R Ingelfinger, J P Vora, S Anderson
Journal: Journal of the American Society of Nephrology (1995)

Progressive deterioration of renal function occurs during normal aging. Previous studies on the aging kidney have demonstrated glomerular hemodynamic changes, specifically, glomerular capillary hypertension, as maladaptations that lead to proteinuria and glomerular sclerosis over time. Aging rats treated with angiotensin-converting enzyme inhibition have relatively less proteinuria and sclerosis, suggesting that age-related changes in renal function may be associated with alterations in the intrarenal renin-angiotensin system, which thus may play a major role in the pathogenesis of these maladaptations. To investigate this possibility, renal and systemic renin-angiotensin systems were examined at an early phase of the aging process (3 months) and at a later phase (12 months) in male Sprague-Dawley rats. Although plasma renin and serum angiotensin-converting enzyme concentrations did not differ significantly, the intrarenal system showed down-regulation of renin mRNA and angiotensin-converting enzyme levels with aging, whereas angiotensinogen levels remained stable. The decrease in renin mRNA appeared to precede the fall in plasma renin concentration in the aging process. Additional studies in 15-month-old rats confirmed that, by this time, both basal and stimulated renal renin release rates were impaired in older rats. Thus, both decreased renin synthesis and impaired renin release underlie the fall in plasma renin with normal aging. This decrease may act to lower intrarenal baseline levels of angiotensin II, an adaptation of likely importance in the modulation of intrarenal vascular tone and tubular function in the aging kidney.
Fine-Scale Exposure to Allergenic Pollen in the Urban Environment: Evaluation of Land Use Regression Approach
Authors: Jan Hjort, Timo T. Hugg, Harri Antikainen, Jarmo Rusanen, Mikhail Sofiev, Jaakko Kukkonen, Maritta S. Jaakkola, Jouni J.K. Jaakkola
Journal: Environmental Health Perspectives (2015)

Despite the recent developments in physically and chemically based analysis of atmospheric particles, no models exist for resolving the spatial variability of pollen concentration at urban scale.
Incidence of hepatocellular carcinoma after seroclearance is not reduced
Authors: Chee‐Kiat Tan
Journal: Hepatology (2016)

Potential conflict of interest: Nothing to report. To the Editor: I read with concern the correction that was recently published in the October issue.1 The correction completely changed one of the key conclusions of the article to the contrary. In the 2010 Hepatology article,2 the authors stated: "Our study is the first to show a significant reduction in the risk of developing HCC after HBsAg clearance," but in the correction published in 2015, we are now told this is an erroneous conclusion because there is, in fact, no significant reduction in the risk of developing hepatocellular carcinoma (HCC) after hepatitis B surface antigen (HBsAg) clearance. I have concerns regarding statistical analysis presented in the correction notice. The new corrected incidence of HCC in patients who had HBsAg seroclearance is 441.6 in 100,000 person‐years (95% confidence interval [CI]: 162.0‐958.0), as opposed to the previously erroneous rate of 36.8 in 100,000 person‐years (95% CI: 13.5‐80.0). The incidence rate of HCC in patients who did not have HBsAg seroclearance remained correct at 195.7 in 100,000 person‐years (95% CI: 141.1‐264.5). Consequently, the comparison had changed from very highly significantly different (P < 0.001) to not significantly different (P = 0.09), despite the numerically huge difference in incidence (441.6 vs. 195.7 not significant when 36.8 vs. 195.7 was very highly significant), obviously attributed to the extremely large 95% CI of the HBsAg seroclearance group (162.0‐958.0). In view of the new large 95% CI of the HBsAg seroclearance group, it may not be statistically meaningful to perform such a statistical comparison. While I appreciate the authors providing a "corrections" notice, I have concerns that many readers will remain unaware of the error and change in conclusions. I would ask the authors to provide a more detailed explanation of the "corrected" data and conclusions.
PTH-141 Pattern of single lymph node metastasis in carcinoma of the oesophagus: Abstract PTH-141 Table 1
Authors: M Navidi, S Lagarde, S Wahed, A Phillips, A Immanuel, N Hayes, M Griffin
Journal: Gut (2015)

<h3>Introduction</h3> The presence of lymphatic dissemination in oesophageal cancer affects prognosis. The relevance of location of an involved solitary lymph node is unclear. The concept of sentinel node guided lymphadenectomy to reduce surgical stress of a transthoracic operation has some advocates. However, the site of solitary lymph node metastasis, is unpredictable. Similarly, metastases to anatomically distant lymph nodes, known as skip lesions, could develop in the early phase of lymphatic invasion. The aim of this study was to examine the pattern of a single named lymph node metastasis in patients with oesophageal adenocarcinoma (AC) or squamous cell carcinoma (SCC) who underwent resection with curative intent. No study to date has investigated this concept. <h3>Method</h3> Results of consecutive patients from a prospectively maintained database were analysed. All patients with potentially curable AC or SCC who underwent a radical two-field, two-stage, transthoracic oesophagectomy were included. Ex-vivo surgical dissection of the specimen was carried out post-operatively by the surgeon, with harvested lymph node stations labelled. This permitted accurate ‘lymph node mapping’. All harvested lymph nodes were examined by a consultant histopathologist. <h3>Results</h3> Between 1995 and 2014 a total of 120 patients with one positive lymph node who had undergone a radical two-field, two-stage oesophagectomy were identified. A median age of 65 (45–80) was observed. Seventy three ACs and 47 SCCs were noted. Twenty three middle oesophageal (19.2%), 54 lower oesophageal (45%) and 43 (35.8%) junctional tumours were resected. There was no difference between patterns of solitary lymphatic metastases between AC and SCC. The pattern and number of solitary lymph node metastasis is as follows: paracardial 34 (28.3%); paraoesophageal 31 (25.8%); left gastric 28 (23.3%); subcarinal/bronchial 10 (8.3%) and truncal/coeliac/splenic 9 (7.5%). Tumour location and corresponding single node metastasis are summarised in Table 1. Median survival for patients with AD and SCC were similar at 45 months and 52 months respectively (p = 0.84). <h3>Conclusion</h3> This study provides further support to the concept that metastasis to anatomically distant lymph nodes (skip metastasis), could develop even in the early phase of lymphatic invasion in oesophageal carcinoma. This unpredictability necessitates a radical resection. This can only be achieved with an extended transthoracic operation to allow a complete two-field lymphadenectomy in order to provide locoregional clearance and a potentially curative resection. <h3>Disclosure of interest</h3> None Declared.
Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia
Authors: Tomoya Fukawa, Benjamin Chua Yan-Jiang, Jason Chua Min-Wen, Elwin Tan Jun-Hao, Dan Huang, Chao-Nan Qian, Pauline Ong, Zhimei Li, Shuwen Chen, Shi Ya Mak, Wan Jun Lim, Hiro-omi Kanayama, Rosmin Elsa Mohan, Ruiqi Rachel Wang, Jiunn Herng Lai, Clarinda Chua, Hock Soo Ong, Ker-Kan Tan, Ying Swan Ho, Iain Beehuat Tan, Bin Tean Teh, Ng Shyh-Chang
Journal: Nature Medicine (2016)
General practice being “eroded” in Scotland, says RCGP
Authors: Bryan Christie
Journal: BMJ (2016)

Patients in Scotland have been told that they “have every right to worry” as the Royal College of General Practitioners (RCGP) accused the Scottish government of deliberately eroding primary care.

Speaking about current policy, Miles Mack, chair of RCGP Scotland, said that the Scottish government sees general practice as dispensable in its current form. This would mean longer delays for patients to see their family doctor, he warned.

Mack said that a decade of cuts to …
Klotho May Ameliorate Proteinuria by Targeting TRPC6 Channels in Podocytes
Authors: Ji-Hee Kim, Jian Xie, Kyu-Hee Hwang, Yueh-Lin Wu, Noelynn Oliver, Minseob Eom, Kyu-Sang Park, Nestor Barrezueta, In-Deok Kong, R. Paul Fracasso, Chou-Long Huang, Seung-Kuy Cha
Journal: Journal of the American Society of Nephrology (2016)

Klotho is a type-1 membrane protein predominantly produced in the kidney, the extracellular domain of which is secreted into the systemic circulation. Membranous and secreted Klotho protect organs, including the kidney, but whether and how Klotho directly protects the glomerular filter is unknown. Here, we report that secreted Klotho suppressed transient receptor potential channel 6 (TRPC6)-mediated Ca 2+ influx in cultured mouse podocytes by inhibiting phosphoinositide 3-kinase-dependent exocytosis of the channel. Furthermore, soluble Klotho reduced ATP-stimulated actin cytoskeletal remodeling and transepithelial albumin leakage in these cells. Overexpression of TRPC6 by gene delivery in mice induced albuminuria, and exogenous administration of Klotho ameliorated the albuminuria. Notably, immunofluorescence and in situ hybridization revealed Klotho expression in podocytes of mouse and human kidney. Heterozygous Klotho-deficient CKD mice had aggravated albuminuria compared with that in wild-type CKD mice with a similar degree of hypertension and reduced clearance function. Finally, disrupting the integrity of glomerular filter by saline infusion-mediated extracellular fluid volume expansion increased urinary Klotho excretion. These results reveal a potential novel function of Klotho in protecting the glomerular filter, and may offer a new therapeutic strategy for treatment of proteinuria.
A controlled study of lifetime prevalence of affective and other psychiatric disorders in bulimic outpatients
Authors: J I Hudson, H G Pope, D Yurgelun-Todd, J M Jonas, F R Frankenburg
Journal: American Journal of Psychiatry (1987)

The authors used structured diagnostic interviews to assess the lifetime prevalence of psychiatric disorders, by DSM-III criteria, among 70 women: 51 outpatients with active bulimia and 19 nonpatient subjects with remitted bulimia. Comparison groups consisted of 24 female outpatients with major depression and 28 nonpsychiatric control subjects. The active and remitted bulimic subjects closely resembled each other, with high lifetime rates of major affective disorder, anxiety disorders, and substance use disorders. Atypical depression was equally common among subjects with major affective disorder in all groups. These results are consistent with previous studies suggesting a phenomenologic relationship between bulimia and major affective disorder.
Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
Authors: Jedd D. Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean Jacques Grob, Charles Lance Cowey, Christopher D. Lao, Dirk Schadendorf, Pier Francesco Ferrucci, Michael Smylie, Reinhard Dummer, Andrew Graham Hill, John B. A. G. Haanen, Michele Maio, Grant A. McArthur, Arvin Yang, Linda Rollin, Christine E. Horak, James M. G. Larkin, F. Stephen Hodi
Journal: Journal of Clinical Oncology (2015)

LBA1 Background: The results of a phase I study in MEL suggested complementary clinical activity with NIVO (a PD-1 checkpoint inhibitor) plus IPI (a CTLA-4 checkpoint inhibitor). Here, we report the results of a randomized, double-blind, phase III trial designed to evaluate NIVO combined with IPI or NIVO alone vs IPI alone in MEL. Methods: Treatment-naïve pts (N = 945) were randomized 1:1:1 to NIVO 1 mg/kg Q2W + IPI 3 mg/kg Q3W for 4 doses followed by NIVO 3 mg/kg Q2W, NIVO 3 mg/kg Q2W + placebo, or IPI 3 mg/kg Q3W for 4 doses + placebo, until progression or unacceptable toxicity. Pts were stratified by PD-L1 status, BRAF mutation status, and M-stage. Co-primary endpoints are progression-free survival (PFS) (reported here) and overall survival (pts continue to be followed). Secondary endpoints include objective response rate (ORR) by RECIST v1.1 and safety. Results: At a minimum follow-up of 9 months, NIVO + IPI and NIVO alone significantly improved PFS and ORR vs IPI (Table). Grade 3-4 drug-related adverse events (AEs) occurred in 55.0%, 16.3%, and 27.3% of pts in the NIVO + IPI, NIVO, and IPI arms, respectively (most commonly diarrhea [9.3%, 2.2%, 6.1%], increased lipase [8.6%, 3.5%, 3.9%], increased alanine aminotransferase [8.3%, 1.3%, 1.6%], and colitis [7.7%, 0.6%, 8.7%]). Drug-related AEs led to discontinuation in 36.4%, 7.7%, and 14.8% of pts in the NIVO + IPI, NIVO, and IPI arms, with 0, 1, and 1 drug-related deaths, respectively. Efficacy outcomes by PD-L1 status will also be presented. Conclusions: NIVO + IPI and NIVO alone had superior clinical activity vs IPI alone. The results with NIVO + IPI and NIVO alone further suggest complementary activity of the two agents. There were no new safety signals or drug-related deaths observed with the combination. Clinical trial information: NCT01844505. [Table: see text]
Obesity Management and Prevention
Authors: Tannaz Moin
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings
Authors: E Hollander, M Fay, B Cohen, R Campeas, J M Gorman, M R Liebowitz
Journal: American Journal of Psychiatry (1988)

Six of eight patients with obsessive-compulsive disorder had an exacerbation of symptoms when given m-chlorophenylpiperazine. Fenfluramine and placebo produced mild improvement. Six patients given intravenous clonidine experienced marked reduction in obsessions. Implications for serotonergic and noradrenergic hypotheses of obsessive-compulsive disorder are discussed.
Mechanical Circulatory Support and Rationale for Future Research—Reply
Authors: Rohan Khera, Saket Girotra
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Caregivers’ Burden and Fatigue During Patients’ (Pts) Treatment with Curative, Concomitant Chemoradiotherapy (Crt) for Locally Advanced Head and Neck Cancer (Lahnc): a Prospective, Observational Study
Authors: C. van Herpen, S.M.C.H. Langenberg, C.C.M. van Opstal, A.N.M. Wymenga, W.T.A. van der Graaf, J.B. Prins
Journal: Annals of Oncology (2014)
Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study
Authors: François Spertini, Gilles DellaCorte, Alexander Kettner, Frédéric de Blay, Lars Jacobsen, Marek Jutel, Margitta Worm, Vincent Charlon, Christophe Reymond
Journal: Journal of Allergy and Clinical Immunology (2016)